Linked Danish records associate GLP-1 treatment with less long-term sickness leave but not with detectable changes in income, participation, or employment over four years.
Research question
Does initiating GLP-1 treatment change labor-market outcomes and public finances?
Method & data
Linked Danish administrative data are analyzed with a matched stacked difference-in-differences design comparing earlier and later treatment initiators.
Main finding
The abstract reports reduced long-term sickness leave and positive fiscal benefits, with no statistically significant or economically meaningful changes in income, participation, or employment.
Why it matters
Health treatments can affect public budgets through work absence even when broader employment margins do not move.
What to verify
The public abstract does not state the identifying assumptions’ diagnostic results or whether effects persist beyond four years.
Show public abstract used for this summary
We estimate the causal impacts of GLP-1 treatment on labor market outcomes using linked Danish administrative data and a matched stacked difference-in-differences design. We compare patients who initiate GLP-1 treatment during the first two years of Semaglutide availability to observably similar patients who initiate four years later. We find that GLP-1 treatment reduces long-term sickness leave by 17.3%. We estimate total fiscal benefits of GLP-1 initiation of approximately 1.3–1.5% of annual labor income per employed individual. We do not detect statistically significant or economically meaningful impacts on income, labor force participation, or employment over four years.